Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001558370-24-012527
Filing Date
2024-08-29
Accepted
2024-08-29 07:07:16
Documents
48
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 6-K rdhl-20240630x6k.htm   iXBRL 6-K 65120
2 EX-99.1 rdhl-20240630xex99d1.htm EX-99.1 242446
3 EX-99.2 rdhl-20240630xex99d2.htm   iXBRL EX-99.2 452087
4 GRAPHIC rdhl-20240630xex99d1001.jpg GRAPHIC 6747
  Complete submission text file 0001558370-24-012527.txt   2892894

Data Files

Seq Description Document Type Size
5 EX-101.SCH rdhl-20240630.xsd EX-101.SCH 38781
6 EX-101.CAL rdhl-20240630_cal.xml EX-101.CAL 40330
7 EX-101.DEF rdhl-20240630_def.xml EX-101.DEF 107504
8 EX-101.LAB rdhl-20240630_lab.xml EX-101.LAB 259617
9 EX-101.PRE rdhl-20240630_pre.xml EX-101.PRE 167667
51 EXTRACTED XBRL INSTANCE DOCUMENT rdhl-20240630x6k_htm.xml XML 343250
Mailing Address 21 HA'ARBA'A STREET TEL AVIV L3 64739
Business Address 21 HA'ARBA'A STREET TEL AVIV L3 64739 972-3-541-3131
RedHill Biopharma Ltd. (Filer) CIK: 0001553846 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3
Type: 6-K | Act: 34 | File No.: 001-35773 | Film No.: 241258554
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)